Active tuberculosis case finding and detection of drug resistance among HIV-infected patients: A cross-sectional study in a TB endemic area, Gondar, Northwest Ethiopia  by Alemayehu, Martha et al.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 1 3 2 –1 3 8
.sc iencedi rect .comAvai lab le at wwwScienceDirect
journal homepage: www.elsev ier .com/ locate / IJMYCOActive tuberculosis case finding and detection
of drug resistance among HIV-infected patients:
A cross-sectional study in a TB endemic area,
Gondar, Northwest Ethiopiahttp://dx.doi.org/10.1016/j.ijmyco.2014.02.004
2212-5531/ 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
* Corresponding author at: Department of Medical Microbiology, University of Gondar, P.O. Box: 196, Gondar, Ethiopia. Tel
776920.
E-mail addresses: marthialex2011@gmail.com (M. Alemayehu), tedybayegelaw@gmail.com (B. Gelaw), ebbaabate@y
(E. Abate), wassieliya@gmail.com (L. Wassie), belyhun@gmail.com (Y. Belyhun), shiferawbekele@gmail.com (S. Bekele), rkempk
edu (R.R. Kempker), hblumbe@emory.edu (H.M. Blumberg), aseffaa@gmail.com (A. Aseffa).Martha Alemayehu a,b,*, Baye Gelaw a, Ebba Abate a, Liya Wassie b,
Yeshambel Belyhun a, Shiferaw Bekele b, Russell R. Kempker c,
Henry M. Blumberg c, Abraham Aseffa b
a Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, P.O. Box: 196, Gondar, Ethiopia
b Armauer Hansen Research Institute, P.O. Box: 1005, Addis Ababa, Ethiopia
c School of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA 30303, USAA R T I C L E I N F O
Article history:
Received 16 January 2014
Received in revised form
7 February 2014
Accepted 9 February 2014
Available online 24 March 2014
Keywords:
Active case finding
HIV
TB
Drug resistance
Northwest EthiopiaA B S T R A C T
Background: Tuberculosis (TB) patients co-infected with human immunodeficiency virus
(HIV) often lack the classic symptoms of pulmonary tuberculosis, making the diagnosis dif-
ficult. Current practices in resource-limited settings often indicate that these co-infected
patients are diagnosed when they clinically manifest disease symptoms, resulting in a
delayed diagnosis and despite continued transmission. The aim of this study is to deter-
mine the prevalence of undiagnosed pulmonary tuberculosis cases through active case
finding and including multidrug-resistant TB (MDR-TB) among HIV-infected patients.
Materials and methods: A total of 250 HIV-infected patients, aged 18 years and above were
evaluated in a cross-sectional design between February 2012 and November 2012. Socio-
demographic and clinical data were collected using a structured questionnaire. Sputum
samples were collected from all participants for acid fast bacilli (AFB) direct smear micros-
copy and Mycobacteria culture. A PCR-based RD9 deletion and genus typing, as well as first-
line anti-TB drug susceptibility testing, was performed for all culture-positive isolates.
Results: Following active TB case finding, a total of 15/250 (6%) cases were diagnosed as TB
cases, of whom 9/250 (3.6%) were detected by both smear microscopy and culture and the
remaining 6/250 (2.4%) only by culture. All the 15 isolates were typed through RD9 typing of
which 10 were Mycobacterium tuberculosis species; 1 belonged to Mycobacterium genus and 4
isolates were non-tuberculous mycobacteria. The prevalence of undiagnosed pulmonary
TB disease among the study participants was 4.4%, which implies the possibility of identi-
fying even more undiagnosed cases through active case finding. A multivariate logistic
regression showed a statistically significant association between the presence of pneumo-
nia infection and the occurrence of TB (OR = 4.81, 95% CI (1.08–21.43), p = 0.04). In addition,.: +251 918
ahoo.com
e@emory.
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only one newly diagnosed TB patient, and MDR-TB was not detected.
Conclusion: The prevalence of undiagnosed pulmonary TB infection among HIV-infected
patients in Gondar was 4.4%. Additionally, the possibility of these undiagnosed TB cases
in the community could also pose a risk for the transmission of the disease, particularly
among family members. Active screening of known HIV-infected individuals, with at least
one TB symptom is recommended, even in persons with opportunistic infections.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) is one of the leading opportunistic infec-
tions that affect people living with human immunodeficiency
virus (HIV) leading to significant morbidity and mortality [1].
People living with HIV are about 21–34 times more likely to
develop TB disease compared with those who are HIV-
negative [2]. TB in such patients is often difficult to diagnose
because of nonspecific symptoms, atypical or normal chest
radiograph findings, negative results of sputum smear
microscopy and lack of culture facilities in resource-limited
settings [3].
Active TB screening can prompt earlier treatment initia-
tion, reducing the burden of disease in an individual and
transmission within the community [4,5]. In 2004, the World
Health Organization (WHO) has recommended routine
screening for active TB disease in all patients living with
HIV, with treatment provided for active TB disease or isonia-
zid preventive therapy (IPT) for latent TB to reduce morbidity
and mortality [6]. However, since this recommendation, only
2.3 million individuals have been screened for TB, of whom
178,000 were offered IPT [2]. Africa accounted for 82% of
new TB cases among people living with HIV [2]. According
to the 2011 WHO tuberculosis report, Ethiopia ranked seventh
among the world’s 22 high-burden countries with an esti-
mated incidence of 333 per 100,000 populations per year [2,7].
In addition, the emergence of multidrug resistance (MDR)
is also one of the threatening factors for many TB control
programs globally [8]. Drug-resistant TB is expected to exist
in countries like Ethiopia where there is high risk of infection
with HIV, as drug resistance has been significantly associated
with HIV infection [9]. According to the WHO estimate, the
prevalence of MDR-TB in Ethiopia has been estimated to be
1.6% among newly diagnosed cases and 12% among retreat-
ment cases [2]. MDR-TB has progressed to extensively-drug
resistant status (XDR-TB) [10] and the latter have evolved in
some parts of the world to totally-drug resistant (TDR-TB)
infections [11]. The presence of XDR-TB has not been thor-
oughly investigated in Ethiopia. Recently, two XDR-TB strains
were reported from a total of 45 MDR-TB cases in a study con-
ducted at St. Peter’s TB Specialized Hospital and Ethiopian
Health and Nutrition Research Institute [12]. TDR-TB-a
yet-to-be-defined infection – is believed to be resistant to all
forms of therapy, and mortality is almost certain [11].
Although many factors such as the degree of immunosup-
pression, high-risk behavior, lifestyle and TB contact history
contribute to the development of active TB in HIV-positivepatients [13–15], delays in early diagnosis of TB can also play
an important role in morbidity and mortality among HIV
patients. To the knowledge of this study, this is the first report
done among HIV-infected patients to assess the prevalence of
undiagnosed pulmonary TB, anti-TB drug susceptibility patterns
and associated risk factors, who attend anti-retroviral (ARV)
clinics in the Gondar area, Ethiopia, through active case
findings.Materials and methods
Study design and participants
A cross-sectional study was conducted between February
2012 and November 2012 among HIV patients attending the
ARV clinic at the Gondar University Hospital, a tertiary-level
teaching and referral hospital in Northwest Ethiopia. A total
of 250 consecutive HIV patients, aged 18 years and above
and who at least had one of the TB symptoms (cough, night
sweats, fever or weight loss), but undiagnosed during their
visit at the clinic were enrolled.
In addition, patients with a history of previous TB and
those on anti-retroviral treatment (ART) or pre-ARTwere also
enrolled. Those patients with severe illness and unable to
provide sputum and who already started anti-TB treatment
or IPT were excluded. Socio-demographic features (Table 1)
and clinical data (Table 2), including chest X-ray findings,
were collected using structured questionnaires.
The clinical presentation of HIV positive cases were
non-specific, such as an acute mononucleosis-like illness
accompanied by fevers, sweats, malaise, lethargy, anorexia,
nausea, myalgia, arthralgia, headache, sore throat, diarrhea,
lymphadenopathy and rash [16].Sputum collection and processing
Three sputum samples (spot-morning-spot samples) were
collected from all eligible participants, pooled and a direct
acid fast bacilli (AFB) smear microscopy was performed using
the conventional Ziehl–Neelsen staining technique at the
Gondar Microbiology Laboratory as described earlier [17].
The remaining aliquots of sputa were transported in a cold
chain from Gondar Microbiology Laboratory to the P3 TB
laboratory facility at Armauer Hansen Research Institute
(AHRI), Addis Ababa, for Mycobacterium culture, RD typing
and drug susceptibility testing.
Table 1 – Socio-demographic characteristics of the study
participants (n = 250) from antiretroviral Clinic at Gondar
University Hospital, Northwest Ethiopia, 2012.
Socio-demographic
variables
Frequency
(n = 250)
Percentage
(%)
Sex
Male 92 36.8
Female 158 63.2
Age, mean (SD) 35.72 (9.42)
Residence area
Urban 210 84.0
Rural 40 16.0
Marital status
Single 47 18.8
Married 111 44.4
Divorced 52 20.8
Widowed 40 16.0
Educational background
Illiterate 98 39.2
Read & write 135 54.0
Higher education 17 6.8
Occupational status
Employed 38 15.2
Unemployed 136 54.4
Retired 4 1.6
Housewife 45 18.0
Daily labor 20 8.0
Farmer 7 2.8
Abbreviation: SD = standard deviation.
Table 2 – Baseline clinical data of the study participants (n = 250
Northwest Ethiopia, 2012.
Characteristics Total n = 250 (%) Tuberculosis
Previous contact with TB 26 (10) 25 (11)
History of TB treatment 73 (29) 69 (29)
Alcohol drinking 29 (12) 27 (11)
Tobacco use 4 (2) 4 (2)
Shisha use 8 (3) 7 (3)
Receiving HAART 167 (67) 161 (67)
Mean household members (IQR) 3.8(2–5) 3.7
WHO clinical stage
I 126(50) 122(51)
II 39(16) 36(15)
III 80(32) 76(32)
IV 5(2) 5(2)
Current OIs
Oral Thrush 37 (15) 36 (15)
Pneumonia 24 (10) 21 (9)
Herpes Zoster 62 (25) 60 (25)
Chest X-ray findings 61 (24) 57 (24)
Infiltrate 14 (6) 13 (5)
Effusion 7 (3) 7 (3)
Cavity 4 (2) 4 (2)
Miliary 2 (1) 2 (1)
TB – tuberculosis; HAART – highly active antiretroviral therapy; IQR – int
Organization.
* TB status was categorized based on the results of a combination of AFB
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Sputum samples were decontaminated and homogenized by
the modified Petroff’s method as described previously [18].
Briefly, about 1 ml of the sediment was inoculated into the
conventional Lowenstein-Jensen (LJ) egg slant medium
containing 0.6% sodium pyruvate and glycerol for primary
isolation. After inoculation, LJ slants were held for 8 weeks
at 37 C and visually inspected for growth every day for the
first week and twice per week thereafter for the total of
8 weeks for the presence of mycobacterial colonies. Micro-
scopic examinations of the colonies were performed using
Ziehl–Neelsen staining method so as to select AFB positive
isolates.
Molecular typing
Heat-killed cells were prepared from AFB positive isolates by
mixing two loops-full of colonies in 200 ll of distilled water
and by heating at 80oC for one hour. Polymerase Chain Reac-
tion (PCR)-based deletion typing was performed to check for
the presence or absence of regions of difference-9 (RD9) so as
to identify Mycobacterium tuberculosis (M. tuberculosis) from
other species of Mycobacteria [19]. The method was applied to
heat-killed mycobacterial suspensions. A multiplex PCR was
designed to amplify the non-deleted RD9 region. Two external
primers (RD9_FlankFW: 5 0-AACACGGTCACGTTGTCGTG-3 0 and
RD9_FlankRev: 5 0-CAAACCAGCAGCTGTCGTTG-3 0) and one
internal reverse primer (RD9_InternalR: 5 0-TTGCTTCCCCGGT
TCGTCTG-30) were used per locus.) from antiretroviral Clinic at Gondar University Hospital,
negative n = 239 (%) Tuberculosis positive* n = 11 (%) p Value
1 (9) 0.88
4 (36) 0.59
2 (18) 0.49
0 0.66
1 (9) 0.26
6 (55) 0.37
5.4 0.52
4(37) 0.63
3(27)
4(36)
0
1 (9) 0.59
3 (27) 0.04
2 (18) 0.60
4 (36) 0.35
1 (9) 0.61
0 0.56
0 0.67
0 0.76
erquartile range; OIs – opportunistic infections; WHO – World Health
smear microscopy, culture, RD9 and genus typing.
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typing was performed from non-deleted RD9 region to further
differentiate species of theM. tuberculosis complex from other
Mycobacterium species. A reference strain of M. tuberculosis,
H37Rv (ATCC 27249) and water were also run simultaneously
with samples in every reaction as positive and negative
controls, respectively.
Drug susceptibility testing (DST)
Indirect drug susceptibility testing was performed for first-
line anti-TB drugs (isoniazid, rifampicin, ethambutol and
streptomycin), based on proportion method on 24-well tissue
culture plates (Becton Dickinson, USA) using Middlebrook
7H10 medium supplemented with glycerol and 10% oleic acid
albumin dextrose catalase (OADC; Becton Dickinson, Sparks,
MD). Primary isolates grown within 2–3 weeks were used for
preparing the suspension, then the DST plates were inocu-
lated by adding 10 ll of the suspension which was adjusted
with McFarland standard. The plates were securely sealed
with Parafilm and incubated at 35 C in a 5% CO2 incubator
with a water reservoir. Drug susceptibility was determined
by visually comparing the drug containing media (1:1 bacte-
rial suspensions) with the drug-free control on which 1:100
bacterial suspensions was inoculated. The drug sensitivity
of the bacterial isolate was later determined using the critical
concentration level as recommended by the WHO 2009 [20].
Statistical analysis
Data analysis was performed using SPSS software packages
Version 20.0 (SPSS Inc., Chicago, 2011, USA). Descriptive
statistics was used to report patient socio-demographics
and clinical data, prevalence of undiagnosed pulmonary TB
and rates of MDR-TB. Logistic regression and odds ratio were
used to measure the degree of association between the differ-
ent variables. A p-value of <0.05 was considered statistically
significant.
Ethical consideration
The study received ethical approval from the ethics board of
the University of Gondar, School of Biomedical and Labora-
tory Sciences, and AHRI/ALERT Ethics Review Committee
and all participants gave written informed consent.
Results
Of the 250 participants who were actively screened for TB, 15
(6%) cases were identified as having TB, of whom 9 were new-
ly detected TB cases and positive by both smear microscopy
and culture, and the remaining were previously treated TB
cases (patients who had a previous history of TB and com-
pleted TB treatment at least 3 months previously and not
identified as TB suspect during the study period) and detected
only using culture. RD9 typing also showed that ten of the
isolates were M. tuberculosis species, one belonged to
Mycobacterium genus, which could not be specified due to
inaccessibility of the test kits and the remaining four isolateswere non-tuberculous mycobacteria, further indicating the
prevalence of undiagnosed pulmonary TB disease in the study
cohort to be 4.4% (11/250).
The overall CD4 T-cell count was relatively higher among
non-TB cases compared with TB cases (Table 3), although
there was no statistically significant association. Logistic
regression analyses showed no significant association
between different variables and risk factors for pulmonary
TB disease, except for the presence of pneumonia
(OR = 4.81, 95% CI [1.08–21.43], p = 0.04) (Table 4).
On the other hand, analyses of drug susceptibility testing
showed that all of the 11 Mycobacterium isolates became sen-
sitive to all first-line anti-TB drugs, except for one isolate,
which was obtained from a newly diagnosed TB case that
was resistant to streptomycin. No MDR-TB was detected in
the study cohort in both newly diagnosed cases and
previously treated TB cases.
Discussion
The current study identified about 4.4% of undiagnosed
pulmonary TB among a cohort of HIV-infected individuals
visiting ART clinics in the Gondar area, where the majority
were also smear positive/culture positive (3.6%) implying the
possibility of identifying evenmore undiagnosed cases through
active case finding. In addition, the possibility of these
undiagnosed TB cases in the community could also pose a
risk for the transmission of the disease, particularly among
familymembers. This observation is relatively higher thanwhat
has been reported from South Africa among HIV-positive gold
miners, where the point prevalence of undiagnosed TB and
the rate of smear-positive TB were 3.8% and 0.4%, respectively
[21]. This difference could also be attributed to the use of IPT
among the South African gold miners that could reduce the
occurrence of symptomatic disease due to TB.
A case-control study conducted in Northwest Ethiopia by
Animut et al. showed that out of 282 TB patients, 54.6%,
23.8% and 21.6% had smear negative, smear positive and
extra pulmonary TB, respectively, and identified several
predictors of HIV counseling and testing among TB patients
which is in contrast to this study [22]. The difference is in this
study all participants were known HIV patients screened for
TB but not TB patients.
On the other hand, a study conducted in one of the
research clinics in Gambia reported a significantly higher
proportion of TB (43.2%) among HIV patients, of whom 66%
had pulmonary TB confirmed by microscopy and/or culture
[23]. In a similar trend, a higher prevalence of pulmonary TB
was reported among HIV-positive patients in Cambodia [24].
Part of these differences in the two reports was mainly due
to differences in inclusion and exclusion criteria, where in
this case all patients who were already diagnosed with TB
and started anti-TB treatments were excluded.
The finding from the RD9 typing also demonstrates that
the dominant causative agent for TB in the study population
was M. tuberculosis, as more than 60% of the isolates were
confirmed to be M. tuberculosis. This has been also evident
from earlier studies conducted in other regions of Ethiopia
[25,26]. This study also evaluated the association of TB
Table 3 – Immunological status of the study participants (n = 250), as depicted by CDþ4 T-cell count, Gondar University Hospital,
Northwest Ethiopia, 2012.
Tuberculosis status
CD4
+ T-cell count Total n = 250 (%) Tuberculosis negative n = 239 (%) Tuberculosis positive n = 11 (%) p value
<200 58 (23) 53 (22) 5 (46) 0.07
>200 192 (77) 186 (78) 6 (56)
Mean CDþ4 T cell (IQR) 363 (211–475) 368 245 0.09
CD – cluster of differentiation; IQR – interquartile range.
Table 4 – Analyses of risk factors for pulmonary TB among study participants (n = 250), Gondar University Hospital,
Northwest Ethiopia, 2012.
Characteristic Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age (year) 1.02 (0.96–1.08) 0.60
Female 1.58 (0.41–6.20) 0.51
Married 0.27 (0.06–1.25) 0.09 0.31 (0.06–1.52) 0.15
Unemployed 0.69 (0.20–2.31) 0.54
Illiterate 0.57 (0.15–2.20) 0.41
Any alcohol use 1.75 (0.36–8.50) 0.49
Previous contact with TB 1.17 (0.14–9.51) 0.89
Household members >4 1.58 (0.47–5.34) 0.46
HIV
WHO stage III/IV vs. I/II 1.12 (0.32–3.92) 0.87
HAART use 0.58 (0.17–1.96) 0.38
CDþ4 T cell count <200 2.93 (0.86–9.96) 0.09 2.54 (0.68–9.56) 0.17
History of TB treatment 1.41 (0.40–4.96) 0.59
Current OIs
Thrush 0.56 (0.07–4.54) 0.59
Pneumonia 3.89 (0.96–15.79) 0.06 4.81 (1.08–21.43)* 0.04*
Herpes Zoster 0.66 (0.24–3.15) 0.61
Symptoms
Fever 0.83 (0.24–2.93) 0.77
Cough 2.31 (0.49–10.92) 0.29
Weight loss 2.62 (0.78–8.87) 0.12 2.38 (0.67–8.43) 0.10
Night sweats 1.76 (0.46–6.80) 0.41
CXR infiltrate 0.58 (0.07–4.84) 0.61
TB – tuberculosis; OR – odds ratio; CI – confidence interval; HAART – highly active antiretroviral therapy; CD – cluster of differentiation; OIs –
opportunistic infections; CXR – chest X-ray.
* Statistically significant.
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dence area, occupation, education, marital status, alcohol intake,
tobacco or shisha use, previous TB contact history, stages of
HIV or ARTuse and CD4 count; however, none of these factors
significantly correlated with the occurrence of TB (p > 0.05).
Similar observations were also reported earlier [27].
All the mycobacterial isolates tested in this study showed
no resistance to all first-line anti-TB drugs, except for one
isolate which was resistant to streptomycin. This is in contrast
to previous MDR-TB reports conducted in the country, which
is about 1.6% among new cases and 12% in re-treatment cases
[9,28] and elsewhere [29–32]. It should be noted from the
current study that only a few HIV positive cases that had at
least one TB symptom but were undiagnosed at the attending
clinic (newly diagnosed) or those who completed TB treat-
ment at least 3 months prior to the study (previously treatedcases, but not retreatment cases) were considered, and hence
a few TB-positive cases were identified, which may underes-
timate the overall prevalence of drug resistance among the
HIV-infected population. On the other hand, a study from
Cambodia showed a decreasing trend of anti-TB drug resis-
tance (48% in 1999 to 7.9% in 2004) since the introduction of
ART drugs [33]. These observations may possibly imply the
fact that the introduction of ART may play a role in limiting
the emergence of anti-TB drug resistance. Despite this, the
observed prevalence in the current study could not be
overlooked, as these identified cases could still be major
sources of infection and transmission in the community.
In addition, TB is the most common opportunistic infec-
tion and is the leading cause of mortality in HIV-infected per-
sons. TB disease has been shown to accelerate the natural
course of HIV disease, and, similarly, HIV infection results in
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 1 3 2 –1 3 8 137a more rapid progression from latent TB infection to TB dis-
ease. However, diagnosing TB in HIV-infected persons is a ma-
jor public health challenge.
In general, considering the observed prevalence of
undiagnosed TB among HIV-positive patients, health
professionals, particularly those working in ART facilities,
should critically evaluate HIV patients clinically regardless
of their ART use and actively screen for TB at least through
microscopic examination of TB to detect cases early and
initiate anti-TB or isoniazid preventive treatments. Further
community-based surveys are warranted to confirm the
current findings.Conflict of interest
The authors declare that they have no competing interests.
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